{"transactions":[{"id":973340,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-12-11T21:32:45.000Z","date":"2025-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":4229,"price":701.51,"value":2966685.79,"ownership":{"direct":true},"balance_after":47833,"source":{"system":"sec-edgar","filing":"0001796226-25-000009","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000009/edgardoc.xml","form_type":"4"}},{"id":976907,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-12-09T21:17:05.000Z","date":"2025-12-05","kind":"grant","planned":false,"acquired":true,"shares":18315,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":18315,"derivative":{"exercise_price":726.71,"expiration_date":"2035-12-05","underlying":"Common Stock","underlying_shares":18315},"source":{"system":"sec-edgar","filing":"0001796226-25-000007","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000007/edgardoc.xml","form_type":"4"}},{"id":976906,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-12-09T21:17:05.000Z","date":"2025-12-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":1699,"price":712.94,"value":1211285.06,"ownership":{"direct":true},"balance_after":52062,"source":{"system":"sec-edgar","filing":"0001796226-25-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000007/edgardoc.xml","form_type":"4"}},{"id":976905,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-12-09T21:17:05.000Z","date":"2025-12-05","kind":"grant","planned":false,"acquired":true,"shares":3715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029."}],"balance_after":53761,"source":{"system":"sec-edgar","filing":"0001796226-25-000007","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000007/edgardoc.xml","form_type":"4"}},{"id":1011033,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-10-31T20:06:57.000Z","date":"2025-10-29","kind":"exercise","planned":false,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vested in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":555.67,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001796226-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000005/edgardoc.xml","form_type":"4"}},{"id":1011032,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-10-31T20:06:57.000Z","date":"2025-10-30","kind":"gift","planned":false,"acquired":false,"shares":1538,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50046,"source":{"system":"sec-edgar","filing":"0001796226-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000005/edgardoc.xml","form_type":"4"}},{"id":1011031,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-10-31T20:06:57.000Z","date":"2025-10-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":32490,"price":648.82,"value":21080161.8,"ownership":{"direct":true},"balance_after":51584,"source":{"system":"sec-edgar","filing":"0001796226-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000005/edgardoc.xml","form_type":"4"}},{"id":1011030,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2025-10-31T20:06:57.000Z","date":"2025-10-29","kind":"exercise","planned":false,"acquired":true,"shares":35000,"price":555.67,"value":19448450.0,"ownership":{"direct":true},"balance_after":84074,"source":{"system":"sec-edgar","filing":"0001796226-25-000005","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000179622625000005/edgardoc.xml","form_type":"4"}},{"id":1327434,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-12-18T21:02:34.000Z","date":"2024-12-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1054,"price":730.81,"value":770273.74,"ownership":{"direct":true},"balance_after":49074,"source":{"system":"sec-edgar","filing":"0001968202-24-000139","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000139/edgardoc.xml","form_type":"4"}},{"id":1338111,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-12-10T21:03:13.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":13472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":13472,"derivative":{"exercise_price":771.64,"expiration_date":"2034-12-06","underlying":"Common Stock","underlying_shares":13472},"source":{"system":"sec-edgar","filing":"0001968202-24-000137","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000137/edgardoc.xml","form_type":"4"}},{"id":1338110,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-12-10T21:03:13.000Z","date":"2024-12-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":492,"price":787,"value":387204.0,"ownership":{"direct":true},"balance_after":50128,"source":{"system":"sec-edgar","filing":"0001968202-24-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000137/edgardoc.xml","form_type":"4"}},{"id":1338109,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-12-10T21:03:13.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":3499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028."}],"balance_after":50620,"source":{"system":"sec-edgar","filing":"0001968202-24-000137","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000137/edgardoc.xml","form_type":"4"}},{"id":1370052,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-11-12T21:03:11.000Z","date":"2024-11-08","kind":"gift","planned":false,"acquired":false,"shares":1185,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47121,"source":{"system":"sec-edgar","filing":"0001968202-24-000134","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000134/edgardoc.xml","form_type":"4"}},{"id":1433024,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":399.66,"expiration_date":"2024-12-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433023,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":331,"price":1159.69,"value":383857.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 331 shares of Company stock on August 14, 2024 at prices ranging from $1,159.21 to $1,159.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433022,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":189,"price":1158.78,"value":219009.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 189 shares of Company stock on August 14, 2024 at prices ranging from $1,158.53 to $1,158.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":48637,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433021,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":178,"price":1157.41,"value":206018.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 178 shares of Company stock on August 14, 2024 at prices ranging from $1,157.13 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":48826,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433020,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":1016,"price":1156.43,"value":1174932.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 1,016 shares of Company stock on August 14, 2024 at prices ranging from $1,156.06 to $1,156.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":49004,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433019,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":402,"price":1155.76,"value":464615.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 402 shares of Company stock on August 14, 2024 at prices ranging from $1,155.04 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":50020,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433018,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":777,"price":1154.66,"value":897170.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 777 shares of Company stock on August 14, 2024 at prices ranging from $1,154.05 to $1,154.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":50422,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433017,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":987,"price":1153.74,"value":1138741.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 987 shares of Company stock on August 14, 2024 at prices ranging from $1,153.07 to $1,153.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":51199,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433016,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":197,"price":1152.36,"value":227014.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 197 shares of Company stock on August 14, 2024 at prices ranging from $1,152.27 to $1,152.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":52186,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433015,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":185,"price":1151.46,"value":213020.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 185 shares of Company stock on August 14, 2024 at prices ranging from $1,151.09 to $1,151.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":52383,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433014,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":844,"price":1150.41,"value":970946.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 844 shares of Company stock on August 14, 2024 at prices ranging from $1,150.10 to $1,150.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":52568,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433013,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":294,"price":1149.6,"value":337982.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 294 shares of Company stock on August 14, 2024 at prices ranging from $1,149.13 to $1,149.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":53412,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433012,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":537,"price":1148.52,"value":616755.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 537 shares of Company stock on August 14, 2024 at prices ranging from $1,148.06 to $1,148.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":53706,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433011,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":51,"price":1146.6,"value":58476.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54243,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433010,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":148,"price":1145.58,"value":169545.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 148 shares of Company stock on August 14, 2024 at prices ranging from $1,145.33 to $1,145.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2024 at each separate price."}],"balance_after":54294,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433009,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":45,"price":1144.89,"value":51520.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54442,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433008,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":79,"price":1143.28,"value":90319.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54487,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433007,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":48,"price":1142.94,"value":54861.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54566,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433006,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":55,"price":1140.31,"value":62717.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54614,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433005,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":13637,"price":1141.49,"value":15566499.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54669,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1433004,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-08-15T20:01:19.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":399.66,"value":7993200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":68306,"source":{"system":"sec-edgar","filing":"0001968202-24-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000119/edgardoc.xml","form_type":"4"}},{"id":1575633,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":399.66,"expiration_date":"2024-12-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575632,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":196,"price":968.2,"value":189767.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 196 shares of Company stock on March 14, 2024 at prices ranging from $968.15 to $968.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575631,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":17,"price":966.3,"value":16427.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":48502,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575630,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":78,"price":965.51,"value":75309.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 78 shares of Company stock on March 14, 2024 at prices ranging from $965.26 to $965.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":48519,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575629,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":1,"price":962.87,"value":962.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":48597,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575628,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":47,"price":961.74,"value":45201.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":48598,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575627,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":512,"price":959.36,"value":491192.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 512 shares of Company stock on March 14, 2024 at prices ranging from $959.13 to $959.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":48645,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575626,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":477,"price":958.34,"value":457128.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 477 shares of Company stock on March 14, 2024 at prices ranging from $958.06 to $958.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":49157,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575625,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":730,"price":957.35,"value":698865.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 730 shares of Company stock on March 14, 2024 at prices ranging from $957.02 to $957.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":49634,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575624,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":1108,"price":956.34,"value":1059624.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 1,108 shares of Company stock on March 14, 2024 at prices ranging from $956.08 to $956.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":50364,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575623,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":545,"price":955.54,"value":520769.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 545 shares of Company stock on March 14, 2024 at prices ranging from $955.02 to $955.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":51472,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575622,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":870,"price":954.66,"value":830554.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 870 shares of Company stock on March 14, 2024 at prices ranging from $954.01 to $954.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":52017,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575621,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":576,"price":953.77,"value":549371.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 576 shares of Company stock on March 14, 2024 at prices ranging from $953.30 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":52887,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575620,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":444,"price":952.4,"value":422865.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 444 shares of Company stock on March 14, 2024 at prices ranging from $952.00 to $952.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":53463,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575619,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-14","kind":"sale","planned":true,"acquired":false,"shares":182,"price":951.92,"value":173249.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 182 shares of Company stock on March 14, 2024 at prices ranging from $951.89 to $951.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price."}],"balance_after":53907,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575618,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":14217,"price":971.82,"value":13816364.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":54089,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1575617,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2024-03-15T20:01:02.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":399.66,"value":7993200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":68306,"source":{"system":"sec-edgar","filing":"0001968202-24-000086","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820224000086/edgardoc.xml","form_type":"4"}},{"id":1711608,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-14T21:10:46.000Z","date":"2023-12-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":7657,"price":856.71,"value":6559828.47,"ownership":{"direct":true},"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001968202-23-000055","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000055/edgardoc.xml","form_type":"4"}},{"id":1715286,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-12T21:05:00.000Z","date":"2023-12-08","kind":"grant","planned":false,"acquired":true,"shares":11473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":11473,"derivative":{"exercise_price":843.79,"expiration_date":"2033-12-08","underlying":"Common Stock","underlying_shares":11473},"source":{"system":"sec-edgar","filing":"0001883850-23-000089","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000089/edgardoc.xml","form_type":"4"}},{"id":1715285,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-12T21:05:00.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":669,"price":844.09,"value":564696.21,"ownership":{"direct":true},"balance_after":55963,"source":{"system":"sec-edgar","filing":"0001883850-23-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000089/edgardoc.xml","form_type":"4"}},{"id":1715284,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-12T21:05:00.000Z","date":"2023-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":5105,"price":844.09,"value":4309079.45,"ownership":{"direct":true},"balance_after":56632,"source":{"system":"sec-edgar","filing":"0001883850-23-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000089/edgardoc.xml","form_type":"4"}},{"id":1715283,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-12T21:05:00.000Z","date":"2023-12-08","kind":"grant","planned":false,"acquired":true,"shares":3199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027."}],"balance_after":61737,"source":{"system":"sec-edgar","filing":"0001883850-23-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000089/edgardoc.xml","form_type":"4"}},{"id":1715282,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-12T21:05:00.000Z","date":"2023-12-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":883,"price":843.79,"value":745066.57,"ownership":{"direct":true},"balance_after":58538,"source":{"system":"sec-edgar","filing":"0001883850-23-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000089/edgardoc.xml","form_type":"4"}},{"id":1720625,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-04","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":270.43,"expiration_date":"2023-12-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720624,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":184,"price":821.46,"value":151148.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 184 shares of Company stock on December 5, 2023 at prices ranging from $821.39 to $821.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":59421,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720623,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":345,"price":820.54,"value":283086.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 345 shares of Company stock on December 5, 2023 at prices ranging from $820.27 to $820.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":59605,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720622,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":973,"price":819.57,"value":797441.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 973 shares of Company stock on December 5, 2023 at prices ranging from $819.03 to $819.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":59950,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720621,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":1333,"price":818.59,"value":1091180.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 1,333 shares of Company stock on December 5, 2023 at prices ranging from $818.07 to $818.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":60923,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720620,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":1881,"price":817.36,"value":1537454.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 1,881 shares of Company stock on December 5, 2023 at prices ranging from $817.04 to $817.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":62256,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720619,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":829,"price":816.46,"value":676845.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 829 shares of Company stock on December 5, 2023 at prices ranging from $816.01 to $816.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":64137,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720618,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":155,"price":815.97,"value":126475.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 155 shares of Company stock on December 5, 2023 at prices ranging from $815.90 to $815.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":64966,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720617,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":58,"price":814.06,"value":47215.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":65121,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720616,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":167,"price":813.66,"value":135881.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 167 shares of Company stock on December 5, 2023 at prices ranging from $813.00 to $813.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":65179,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720615,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":372,"price":812.57,"value":302276.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 372 shares of Company stock on December 5, 2023 at prices ranging from $812.26 to $812.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 5, 2023 at each separate price."}],"balance_after":65346,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720614,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":103,"price":811.37,"value":83571.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":65718,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720613,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":136,"price":810.38,"value":110211.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":65821,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720612,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-04","kind":"tax_withholding","planned":true,"acquired":false,"shares":13464,"price":813.58,"value":10954041.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":65957,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1720611,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-12-06T21:02:23.000Z","date":"2023-12-04","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":270.43,"value":5408600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":79421,"source":{"system":"sec-edgar","filing":"0001968202-23-000046","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000046/edgardoc.xml","form_type":"4"}},{"id":1741506,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":20000,"derivative":{"exercise_price":270.43,"expiration_date":"2023-12-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741505,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":19,"price":805,"value":15295.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":59421,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741504,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":19,"price":804.89,"value":15292.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":59440,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741503,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":330,"price":803.38,"value":265115.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 330 shares of Company stock on November 14, 2023 at prices ranging from $803.18 to $803.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":59459,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741502,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":347,"price":802.63,"value":278512.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 347 shares of Company stock on November 14, 2023 at prices ranging from $802.17 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":59789,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741501,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":877,"price":801.56,"value":702968.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 877 shares of Company stock on November 14, 2023 at prices ranging from $801.01 to $801.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":60136,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741500,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":382,"price":800.55,"value":305810.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 382 shares of Company stock on November 14, 2023 at prices ranging from $800.31 to $800.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":61013,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741499,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":1601,"price":799.48,"value":1279967.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 1,601 shares of Company stock on November 14, 2023 at prices ranging from $799.00 to $799.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":61395,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741498,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":1614,"price":798.63,"value":1288988.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 1,614 shares of Company stock on November 14, 2023 at prices ranging from $798.00 to $798.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":62996,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741497,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":204,"price":797.79,"value":162749.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 204 shares of Company stock on November 14, 2023 at prices ranging from $797.09 to $797.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":64610,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741496,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":347,"price":795.38,"value":275996.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 347 shares of Company stock on November 14, 2023 at prices ranging from $795.02 to $795.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":64814,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741495,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-14","kind":"sale","planned":true,"acquired":false,"shares":752,"price":794.57,"value":597516.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 752 shares of Company stock on November 14, 2023 at prices ranging from $794.03 to $794.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 14, 2023 at each separate price."}],"balance_after":65161,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741494,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-13","kind":"tax_withholding","planned":true,"acquired":false,"shares":13508,"price":795.69,"value":10748180.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":65913,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1741493,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-11-15T21:02:48.000Z","date":"2023-11-13","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":270.43,"value":5408600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023."}],"balance_after":79421,"source":{"system":"sec-edgar","filing":"0001968202-23-000042","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000042/edgardoc.xml","form_type":"4"}},{"id":1898658,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2023-05-10T20:08:02.000Z","date":"2023-05-09","kind":"gift","planned":false,"acquired":false,"shares":1326,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":59421,"source":{"system":"sec-edgar","filing":"0001968202-23-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000196820223000013/edgardoc.xml","form_type":"4"}},{"id":2080316,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-20T21:08:16.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":15238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":15238,"derivative":{"exercise_price":726.53,"expiration_date":"2032-12-16","underlying":"Common Stock","underlying_shares":15238},"source":{"system":"sec-edgar","filing":"0001883850-22-000135","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000135/edgardoc.xml","form_type":"4"}},{"id":2080315,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-12-20T21:08:16.000Z","date":"2022-12-16","kind":"grant","acquired":true,"shares":4129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026."}],"balance_after":60747,"source":{"system":"sec-edgar","filing":"0001883850-22-000135","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000135/edgardoc.xml","form_type":"4"}},{"id":2088765,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-12-13T21:12:02.000Z","date":"2022-12-09","kind":"tax_withholding","acquired":false,"shares":492,"price":753.28,"value":370613.76,"ownership":{"direct":true},"balance_after":56618,"source":{"system":"sec-edgar","filing":"0001883850-22-000120","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000120/edgardoc.xml","form_type":"4"}},{"id":2115305,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-14","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":179.13,"expiration_date":"2022-12-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115304,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":10,"price":749.92,"value":7499.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57110,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115303,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":100,"price":744.01,"value":74401.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57120,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115302,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":21,"price":742.25,"value":15587.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57220,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115301,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":66,"price":741.61,"value":48946.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of  66 shares of Company stock on November 15, 2022 at prices ranging from $741.61 to $741.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price."}],"balance_after":57241,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115300,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":2,"price":736.4,"value":1472.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57307,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115299,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":64,"price":734.59,"value":47013.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57309,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115298,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":21,"price":733.42,"value":15401.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 21 shares of Company stock on November 15, 2022 at prices ranging from $733.41 to $733.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price."}],"balance_after":57373,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115297,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":78,"price":732.4,"value":57127.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":57394,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}},{"id":2115296,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":71844,"kind":"person","name":"MURPHY ANDREW J","position":1,"cik":"0001796226","reported_name":"MURPHY ANDREW J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP Research"}}],"security":"Common Stock","published_at":"2022-11-16T21:01:36.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":532,"price":731.49,"value":389152.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 532 shares of Company stock on November 15, 2022 at prices ranging from $731.03 to $731.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 15, 2022 at each separate price."}],"balance_after":57472,"source":{"system":"sec-edgar","filing":"0001883850-22-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000096/edgardoc.xml","form_type":"4"}}],"next_cursor":"2022-11-16T21:01:36.000000Z,2115296"}